We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The company has acquired an Ambr 250, added three single use bioreactors (SUBs) to support process scale-up, preclinical toxicology batch and early cGMP clinical trial supplies at 250L to 1000L scale in its current facility.
Stempeutics Research has announced that it has signed a strategic deal with Kemwell Biopharma for global commercialisation of its stem cell product Stempeucel.